Nothing Special   »   [go: up one dir, main page]

HK1206251A1 - Human anti-cd27 antibodies, methods and uses cd27 - Google Patents

Human anti-cd27 antibodies, methods and uses cd27

Info

Publication number
HK1206251A1
HK1206251A1 HK15106811.7A HK15106811A HK1206251A1 HK 1206251 A1 HK1206251 A1 HK 1206251A1 HK 15106811 A HK15106811 A HK 15106811A HK 1206251 A1 HK1206251 A1 HK 1206251A1
Authority
HK
Hong Kong
Prior art keywords
antibodies
methods
human anti
human
Prior art date
Application number
HK15106811.7A
Other languages
English (en)
Chinese (zh)
Inventor
John Chen
Johan Fransson
Natalie Fursov
Damon Hamel
Thomas Malia
Galina Obmolova
Tatiana Ort
Michael Rycyzyn
Michael Scully
Raymond Sweet
Alexey Teplyakov
John Wheeler
Juan Carlos Almagro
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of HK1206251A1 publication Critical patent/HK1206251A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK15106811.7A 2012-03-15 2015-07-17 Human anti-cd27 antibodies, methods and uses cd27 HK1206251A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261611332P 2012-03-15 2012-03-15
PCT/US2013/031314 WO2013138586A1 (en) 2012-03-15 2013-03-14 Human anti-cd27 antibodies, methods and uses

Publications (1)

Publication Number Publication Date
HK1206251A1 true HK1206251A1 (en) 2016-01-08

Family

ID=49157853

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15106811.7A HK1206251A1 (en) 2012-03-15 2015-07-17 Human anti-cd27 antibodies, methods and uses cd27

Country Status (28)

Country Link
US (6) US9102737B2 (ru)
EP (1) EP2825200A4 (ru)
JP (1) JP6487839B2 (ru)
KR (1) KR102153374B1 (ru)
CN (1) CN104284678B (ru)
AR (1) AR090356A1 (ru)
AU (1) AU2013232087B2 (ru)
BR (2) BR112014022812A2 (ru)
CA (1) CA2867299C (ru)
CL (1) CL2014002416A1 (ru)
CO (1) CO7071095A2 (ru)
CR (1) CR20140415A (ru)
EA (1) EA030828B1 (ru)
EC (1) ECSP14018641A (ru)
GT (1) GT201400193A (ru)
HK (1) HK1206251A1 (ru)
JO (1) JO3787B1 (ru)
MX (1) MX363946B (ru)
MY (1) MY175224A (ru)
NZ (1) NZ629697A (ru)
PE (1) PE20142242A1 (ru)
PH (2) PH12014502011B1 (ru)
SG (2) SG10201710574UA (ru)
TW (2) TW201730214A (ru)
UA (1) UA121844C2 (ru)
UY (1) UY34680A (ru)
WO (1) WO2013138586A1 (ru)
ZA (2) ZA201407440B (ru)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA024701B1 (ru) 2010-04-13 2016-10-31 Селлдекс Терапьютикс Инк. Антитела, связывающие cd27 человека, и их применение
RU2604196C2 (ru) 2011-03-16 2016-12-10 арДЖЕН-ИКС Н.В. Антитела против cd70
WO2014140374A2 (en) * 2013-03-15 2014-09-18 Novo Nordisk A/S Monovalent cd27 antibodies
TWI713453B (zh) 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
FR3025517B1 (fr) * 2014-09-10 2016-12-23 Repropharm Ligands potentialisants de la bioactivite des gonadotrophines
US20180244792A1 (en) * 2015-09-10 2018-08-30 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Anti-fibrotic effect of cd70
MA43053A (fr) 2015-09-30 2018-08-08 Janssen Biotech Inc Anticorps antagonistes se liant spécifiquement au cd40 humain et procédés d'utilisation
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
WO2017068192A1 (en) * 2015-10-23 2017-04-27 Apogenix Ag Single-chain cd27-receptor agonist proteins
US20170233480A1 (en) 2015-12-31 2017-08-17 Development Center For Biotechnology Anti-vegfr antibody and uses thereof
SG11201808821WA (en) 2016-04-18 2018-11-29 Celldex Therapeutics Inc Agonistic antibodies that bind human cd40 and uses thereof
CA3026477A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 antibodies
JOP20190055A1 (ar) * 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
CN108473586B (zh) * 2016-09-29 2021-09-03 江苏恒瑞医药股份有限公司 抗cd27抗体、其抗原结合片段及其医药用途
IL267589B2 (en) * 2016-12-23 2024-11-01 Macrogenics Inc ADAM9 binding molecules and methods of their use
US11166985B2 (en) 2017-05-12 2021-11-09 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
AU2018367896B2 (en) 2017-05-12 2023-06-01 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
CN111108120A (zh) * 2017-07-03 2020-05-05 财团法人生物技术开发中心 抗人类血管内皮生长因子受体的抗体及其应用
WO2019037131A1 (zh) * 2017-08-25 2019-02-28 深圳市博奥康生物科技有限公司 一种cd27真核表达载体的构建及其高表达细胞株的制备
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
US11560421B2 (en) * 2018-02-09 2023-01-24 Osaka University Broad-spectrum monoclonal antibodies against chikungunya virus E1 structural protein
TWI745670B (zh) * 2018-03-28 2021-11-11 大陸商江蘇恒瑞醫藥股份有限公司 抗cd27抗體、其抗原結合片段及其醫藥用途
US12110337B2 (en) 2018-04-04 2024-10-08 Bristol-Myers Squibb Company Anti-CD27 antibodies and uses thereof
US11795230B2 (en) 2018-04-13 2023-10-24 Dingfu Biotarget Co., Ltd. Anti-CD27 antibodies and use thereof
US20210198374A1 (en) 2018-04-17 2021-07-01 Celldex Therapeutics, Inc. Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
KR20210008502A (ko) 2018-05-11 2021-01-22 크리스퍼 테라퓨틱스 아게 암을 치료하기 위한 방법 및 조성물
MA52889A (fr) 2018-06-15 2021-04-21 Flagship Pioneering Innovations V Inc Augmentation de l'activité immunitaire par modulation de facteurs de signalisation post-cellulaires
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
WO2020123444A1 (en) 2018-12-11 2020-06-18 Celldex Therapeutics, Inc. Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy
TWI848030B (zh) 2018-12-18 2024-07-11 比利時商阿根思公司 Ｃｄ７０組合治療
WO2020185952A1 (en) * 2019-03-11 2020-09-17 xCella Biosciences, Inc. Cd27-binding antibodies and uses thereof
MA55797A (fr) 2019-04-30 2022-03-09 Crispr Therapeutics Ag Thérapie cellulaire allogénique de malignités de lymphocytes b à l'aide de lymphocytes t génétiquement modifiés ciblant cd19
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
TW202112812A (zh) 2019-05-24 2021-04-01 香港商安立璽榮生醫(香港)有限公司 Csf1r抗體、il10融合蛋白及其用途
EP4076434A1 (en) 2019-12-17 2022-10-26 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
JP2023532339A (ja) 2020-06-29 2023-07-27 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド サノトランスミッションを促進するためにエンジニアリングされたウイルス及び癌の処置におけるそれらの使用
CN112646029B (zh) * 2020-12-30 2022-07-29 深圳清华大学研究院 成熟脑源性神经营养因子的抗体及其应用和诊断试剂盒
CA3214085A1 (en) 2021-03-31 2022-10-06 Darby Rye Schmidt Thanotransmission polypeptides and their use in treating cancer
CN116120451A (zh) * 2021-06-17 2023-05-16 南京蓝盾生物科技有限公司 抗cd70内化的抗体、抗体偶联物及其应用
CA3224374A1 (en) 2021-06-29 2023-01-05 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
WO2023178192A1 (en) 2022-03-15 2023-09-21 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
WO2024054992A1 (en) 2022-09-09 2024-03-14 Bristol-Myers Squibb Company Methods of separating chelator
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
CN118667002A (zh) * 2023-03-16 2024-09-20 上海赛金生物医药有限公司 抗cd27单克隆抗体及其应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218525B1 (en) 1988-02-25 2001-04-17 The General Hospital Corporation Nucleic acid encoding CD28
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
TW205553B (ru) 1991-04-25 1993-05-11 Chugai Pharmaceutical Co Ltd
ES2227512T3 (es) 1991-12-02 2005-04-01 Medical Research Council Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
US5573924A (en) 1992-09-08 1996-11-12 Immunex Corporation CD27 ligand
WO2001058953A2 (en) 2000-02-11 2001-08-16 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Identification of a domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function
US6982361B1 (en) 2000-02-25 2006-01-03 The Regents Of The University Of California Method of screening a compound for anxiolytic activity in an Apolipoprotein e knockout animal
AU2002239422B2 (en) 2000-11-30 2006-12-07 E. R. Squibb & Sons, L.L.C. Transgenic transchromosomal rodents for making human antibodies
JP2005512962A (ja) 2001-09-20 2005-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗ｐｄｇｆ抗体および設計抗体の産生方法
AU2003210266A1 (en) 2002-02-14 2003-09-04 Bioinvent International Ab Treatment, diagnosis and imaging of disease
AU2004213432A1 (en) 2003-02-14 2004-09-02 Sagres Discovery, Inc. Novel therapeutic targets in cancer
WO2006117910A1 (ja) 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. 抗血小板膜糖蛋白質ⅵモノクローナル抗体
US20110129412A1 (en) 2005-06-02 2011-06-02 Astrazeneca Ab Antibodies Directed to CD20 and Uses Thereof
GB0620894D0 (en) 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
EP2090320A1 (en) 2008-02-15 2009-08-19 Helmholtz-Zentrum für Infektionsforschung GmbH Ligands of the Natural Killer (NK) cell surface marker CD27 and therapeutic uses thereof
JP5425775B2 (ja) * 2008-06-30 2014-02-26 協和発酵キリン株式会社 抗ｃｄ２７抗体
EP2520589B1 (en) * 2009-12-29 2018-11-07 Kyowa Hakko Kirin Co., Ltd. Anti-cd27 antibody
EA024701B1 (ru) * 2010-04-13 2016-10-31 Селлдекс Терапьютикс Инк. Антитела, связывающие cd27 человека, и их применение
CA2804550C (en) * 2010-07-09 2021-01-05 Bionovion Holding B.V. Agonistic antibody to cd27

Also Published As

Publication number Publication date
TW201345922A (zh) 2013-11-16
US20240141055A1 (en) 2024-05-02
CA2867299C (en) 2019-08-27
TW201730214A (zh) 2017-09-01
US11732050B2 (en) 2023-08-22
MX363946B (es) 2019-04-09
US10689453B2 (en) 2020-06-23
UY34680A (es) 2013-09-30
BR112014022812A2 (pt) 2017-07-18
US9102737B2 (en) 2015-08-11
AU2013232087B2 (en) 2018-02-08
TWI576354B (zh) 2017-04-01
JP2015511965A (ja) 2015-04-23
BR122020002414B1 (pt) 2022-03-03
JP6487839B2 (ja) 2019-03-20
SG11201405437QA (en) 2014-10-30
WO2013138586A1 (en) 2013-09-19
NZ629697A (en) 2017-01-27
US20130243795A1 (en) 2013-09-19
ZA201500887B (en) 2016-01-27
EP2825200A1 (en) 2015-01-21
MY175224A (en) 2020-06-16
PH12014502011A1 (en) 2014-11-24
CN104284678A (zh) 2015-01-14
KR102153374B1 (ko) 2020-09-10
SG10201710574UA (en) 2018-02-27
ECSP14018641A (es) 2018-10-31
CL2014002416A1 (es) 2015-01-16
AR090356A1 (es) 2014-11-05
PH12014502011B1 (en) 2014-11-24
CR20140415A (es) 2014-11-18
UA121844C2 (uk) 2020-08-10
US10301392B2 (en) 2019-05-28
ZA201407440B (en) 2016-07-27
EA030828B1 (ru) 2018-10-31
US20170320957A1 (en) 2017-11-09
MX2014011100A (es) 2014-12-05
US20150299330A1 (en) 2015-10-22
KR20140133940A (ko) 2014-11-20
GT201400193A (es) 2017-06-14
EA201491700A1 (ru) 2015-02-27
EP2825200A4 (en) 2015-08-26
CN104284678B (zh) 2018-04-24
US20200277393A1 (en) 2020-09-03
PH12017501908A1 (en) 2018-10-01
CA2867299A1 (en) 2013-09-19
PE20142242A1 (es) 2015-01-08
US20190248910A1 (en) 2019-08-15
PH12017501908B1 (en) 2018-10-01
AU2013232087A1 (en) 2014-09-25
JO3787B1 (ar) 2021-01-31
US9683046B2 (en) 2017-06-20
CO7071095A2 (es) 2014-09-30

Similar Documents

Publication Publication Date Title
HK1206251A1 (en) Human anti-cd27 antibodies, methods and uses cd27
ZA201407927B (en) Anti-egfr antibodies and uses thereof
HK1207092A1 (en) Anti-hla-b27 antibodies and uses thereof -hla-b27
EP2822592A4 (en) SPECIFIC TGF-1 ANTIBODIES AND METHODS AND USES THEREOF
HRP20190358T1 (hr) Antitijela protiv asic1 i njihova primjena
ZA201500457B (en) Anti-kit antibodies and uses thereof
GB201115529D0 (en) Antibodies, uses and methods
GB201115280D0 (en) Antibodies, uses and methods
EP2849790A4 (en) ACTIVE CONJUGATES, CONJUGATION PROCEDURES AND USES THEREOF
HK1213455A1 (zh) 醫療用緊固件
HK1210913A1 (en) Particles, methods and uses thereof
HK1205523A1 (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof ---1(big-et-1)
EP2813495A4 (en) 2-ARYLBENZOFURAN-7-FORMAMIDE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND USE THEREOF
AU343512S (en) Human model
GB201223330D0 (en) Products, methods and uses
EP2837624A4 (en) 4-SUBSTITUTE-2-HYDROXYLMORPHOLIN-3-ON AND METHOD OF MANUFACTURING THEREOF
EP2900693A4 (en) ADCC-mediating antibodies, combinations and uses thereof
GB201208372D0 (en) Antibodies and uses thereof